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A simple, reliable, and sensitive kinetic spectrophotometric method was developed for determination of eight cephalosporin
antibiotics, namely, Cefotaxime sodium, Cephapirin sodium, Cephradine dihydrate, Cephalexin monohydrate, Ceftazidime
pentahydrate, Cefazoline sodium, Ceftriaxone sodium, and Cefuroxime sodium. The method depends on oxidation of each of
studied drugs with alkaline potassium permanganate. The reaction is followed spectrophotometrically by measuring the rate of
change of absorbance at 610nm. The initial rate and ﬁxed time (at 3 minutes) methods are utilized for construction of calibration
graphs to determine the concentration of the studied drugs. The calibration graphs are linear in the concentration ranges 5–
15μgmL
−1 and 5–25μgmL
−1 using the initial rate and ﬁxed time methods, respectively. The results are validated statistically and
checked through recovery studies. The method has been successfully applied for the determination of the studied cephalosporins
in commercial dosage forms. Statistical comparisons of the results with the reference methods show the excellent agreement and
indicate no signiﬁcant diﬀerence in accuracy and precision.
Copyright © 2009 Mahmoud A. Omar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cephalosporins consist of a fused β-lactam-Δ3-dihydroth-
iazine two-ring system, known as 7-aminocephalosporanic
acids(7-ACAs)andvaryintheirsidechainsubstituentsatC3
(R2) and C7 (acylamido, R1). The chemical structure of the
studiedcephalosporinsinthisworkisshowninTable 1.They
are used for treatment of infection caused by both gram-
negative and gram-positive bacteria [1, 2]. A wide variety
of analytical methods have been reported for determination
of cephalosporins in pure form, in pharmaceutical prepara-
tions, and in biological ﬂuids. These methods include spec-
trophotometry [2–5], atomic absorption spectrophotometry
[6], ﬂuorometry [7–12], liquid chromatography [13–20],
Micellar electrokinetic capillary chromatography [21, 22],
chemiluminescence [23–28], potentiometric [29, 30], and
polarographic [31–34] methods. Kinetic spectrophotomet-
ric methods became of great interest in chemical and
pharmaceutical analyses [35] .T h el i t e r a t u r ei ss t i l lp o o r
in analytical procedure based on kinetics, especially for
determination of drug in commercial dosage forms. We
aimed to improve on the current methods by employing the
kinetic colorimetric oxidation of cephalosporins to increase
selectivity, avoid interference of colored and/or turbidity
background of samples and consequently determination of
low concentration of the cited drugs as possible.
2. Experimental
2.1. Apparatus. Spectronic Genesys 2PC. Ultraviolet/Visible
spectrophotometer (Milton Roy Co, USA) with matched
1cm quartz cell was used for all measurements connected to
IBM computer loaded with winspec application software.
2.2. Materials and Reagents. All the materials were of
analytical reagent grade, and the solutions were prepared
with double-distilled water. Samples of cephalosporin were
generously supplied by their respective manufacturers and
were used without further puriﬁcation.
(i) Cephalexin monohydrate, Ceftazedime pentahydra-
te, and Cefuroxime sodium (Galaxowelcome Egypt,
S.A.E, El Salam City, Cairo, Egypt).
(ii) Cephapirin sodium, Cefazoline sodium (Bristol My-
ers- Squib Pharmaceutical Co., Cairo, Egypt).2 International Journal of Analytical Chemistry
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(iii) Cefotaxime sodium, cephradine, and Ceftriaxone
sodium (EIPICO, Tenth of Ramadan City, Cairo,
Egypt).
The purity of authentic samples was checked by UV assay
methods and was not less than 99.26 ± 0.72.
(i) Potassiumpermanganate(Merck,Germany);6×10
−3
Molar solution was prepared by dissolving 100mg in
100mL of double-distilled water followed by boiling
and ﬁltration through sintered glass.
Potassiumpermanganatesolutionshouldbefreshlyprepared
and its molarity was checked titrimetrically.
(i) Sodium hydroxide (El Nasr chemical co., Abuo
Zabbel, Egypt); 0.75M prepared by dissolving 3g in
100mL of double-distilled water.
(ii) Methanol (Merck, Darmstadt, Germany).
2.3. Pharmaceutical Formulations. The following available
commercial preparations were analyzed.
Ceporex tablets and vials, Fortam vials and Zinnat vials
(Galoxowelcome Egypt, S.A.E, El Salam City, Cairo, Egypt),
labeled to contain 250mg cephalexin monohydrate per
tablet and 500mg cephalexin sodium equivalent to 500mg
cephalexin monohydrate per vial, 250mg ceftazidime pen-
tahydrate per vial, and 250mg cefuroxime sodium per vial,
respectively. Cefatrexyl vials, Totacef vials and Velosef tablets
and suspensions (Bristol Myers-Squibb Pharmaceutical Co.,
Cairo, Egypt), labeled to contain 500mg cephapirin sodium
per vial, 500mg cefazoline sodium per vial, and 500mg
cephradine per tablet and suspensions, respectively. Cefotax
vials(EIPICO.TenthofRamadanCity,Cairo,Egypt),labeled
to contain 250mg cefotaxime sodium per vial. Ceftriaxone
vials (Novartis Pharma S.A.E, Cairo, Egypt), labeled to
contain 500mg ceftriaxone sodium per vial.
2.4. Preparation of Standard Solution. Stock solution con-
taining 1mgmL−1 of each cephalosporins was prepared in
double-distilled water, working standard solutions contain-
ing 100μgmL −1 were prepared by suitable dilution of the
stock solutions with double-distilled water.
2.5. Recommended Procedure for Cephalosporins
Determination
2.5.1. Initial Rate Method. Aliquots of 50–150μgmL −1 of
studied cephalosporins test solutions were pipetted into
a series of 10mL volumetric ﬂask. 1.2mL of sodium
hydroxide solution (0.75M) was added followed by 3.0mL
of potassium permanganate solution (6 × 10
−3 M) to each
ﬂask and then diluted to the volume with double-distilled
water at 30 ± 1◦C. The content of mixture of each ﬂask
was mixed well and the increase in absorbance at 610nm
was recorded as a function of time for 15 minutes against
reagentblanktreatedsimilarly.Theinitialrateofthereaction
(ν)a td i ﬀerent concentrations was obtained from the slope
of the tangent to absorbance time curves. The calibration
graphs were constructed by plotting the logarithm of the
initial rate of the reaction (log ν) versus logarithm of molar
concentration of the studied drugs (log C).
2.5.2. Fixed Time Method. In this method, the absorbance of
each sample solution at preselected ﬁxed time (3 minutes)
was accurately measured and plotted against the ﬁnal
concentration of the drug.
2.6. Determination of the Studied Drugs in Pharmaceutical
Formulations
2.6.1. Procedure for Tablets. An accurately weighed amount
equivalent to 100.0mg of each drug from composite of 20
powdered tablets was transferred into a 100mL volumetric
ﬂask. Dissolved in about 20mL methanol, swirled, and
sonicated for 10 minutes, the resultant mixture was ﬁltered
into round bottom ﬂask for removal of any pharmaceutically
“inert” ingredients (cellulose, disaccharides) that could be
subject to oxidation by permanganate. The residue was
washed thoroughly with about 5mL methanol and the
combined ﬁltrate as well as washing solutions was subjected
to evaporation under vacuum till dryness. The residue
lifted was dissolved in about 20mL distilled water and
ﬁltered into 100mL volumetric ﬂask. The ﬁlter paper was
washed thoroughly with double distilled water, and then the
combined ﬁltrate as well as washing solutions was mixed
well and completed to volume with the same solvent to
obtain solution of 1.0mgmL
−1. The ﬁnal solution was
diluted quantitatively with the same solvent to obtain
workingstandardsolutionof100.0μgmL
−1,thenthegeneral
procedure was followed.
2.6.2. Procedure for Capsules and Suspension. The contents
of 20 capsules were evacuated and well mixed. Then an
accuratelyweighedamountequivalentto100.0mgevacuated
capsules or dry powder suspension of each drug was
transferredintoa100mLbeaker,andthentheprocedurewas
continued as described under tablets.
2.6.3. Procedure for Vials. A 100.0mg quantity of each vial
was transferred into a 100mL volumetric ﬂask, dissolved,
and completed to the mark with double-distilled water
to obtain solution of 1.0mgmL−1. Further dilutions with
double-distilled water were made to obtain sample solutions
(100.0 μgmL −1), then the general procedure was followed.
3. Results and Discussion
Potassium permanganate as strong oxidizing agent has been
used in oxidimetric analytical method for determination
of many compounds [36–39]. During the course of the
reaction, the valence of manganese changes. The heptava-
lent manganese ion changes to the green color (Mn VI),
while in neutral and acidic medium, the permanganate
is further reduced to colorless (Mn II). The behavior of
permanganate was the basis for its uses in development
of spectrophotometric method. The absorption spectrum
of aqueous potassium permanganate solution in alkaline4 International Journal of Analytical Chemistry
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Figure 1: Absorption spectra of (a) alkaline potassium perman-
ganate (6 × 10
−3 M) (b) cefotaxime (15μgmL −1)a n d( c )t h e
reaction product.
medium exhibited an absorption band at 530nm. The
additions of any of the studied drugs to this solution produce
a new characteristic band at 610nm (Figure 1). This band is
due to formation of manganate ion, which resulted from the
oxidation of cephalosporin by potassium permanganate in
alkaline medium. The intensity of the color increases with
time; therefore a kinetically based method was developed
for determination of cephalosporins in their pharmaceutical
dosage formulations. The diﬀerent variables that aﬀect the
formation of manganate ion were studied and optimized.
3.1. Eﬀect of Potassium Permanganate Concentration. The
absorbance increases substantially with increasing the con-
centration of potassium permanganate (Figure 2). Maxi-
mum absorbance was obtained when 2.5mL of 6 × 10
−3 M
of potassium permanganate was used. Thus, the adoption
of 3mL of potassium permanganate in the ﬁnal solution
proved to be adequate for the maximum concentration of
cephalosporinusedindeterminationprocess(theconcentra-
tion of the ﬁnal assay was 1.8 × 10
−3 M).
3.2. Eﬀect of Sodium Hydroxide Concentration. Maximum
absorption was obtained when 1mL of 0.75M NaOH was
used. Over this volume no change in absorbance could be
detected. So 1.2mL of 0.75M of NaOH was used as an
optimum value (Figure 3).
3.3. Eﬀect of Temperature. At room temperature the reaction
rate increases substantially with time, although heating the
solution was found to increase the rate of the reaction how-
everbutMnO2 wasprecipitated,thereforeroomtemperature
was selected as the optimum temperature.
3.4. Stoichiometry and Reaction Mechanism. The stoichio-
metric ratio between potassium permanganate and each of
investigated cephalosporins was determined by Job’s method
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Figure 2: Eﬀect of potassium permanganate (3 × 10
−6)o nt h e
reaction between the investigated cephalosporins (15μgmL −1)a n d
alkaline potassium permanganate.
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Figure 3:Eﬀectofsodiumhydroxideconcentration(0.75M)onthe
reaction between the investigated cephalosporins (15μgmL −1)a n d
alkaline potassium permanganate.
[40, 41] and was found to be 1 : 1 (Figure 4). Cephalosporins
were found to be susceptible for oxidation with alkaline
potassium permanganate producing a green color peaking
at 610nm. Therefore, the reaction mechanism is proposed
on the basis of the literature background (39) and our
experimental study as shown in Scheme 1.
The opening of the β-lactam ring by the hydroxyl ion
proceeds via intermediate and result in the formation of
cephalosporoic acid and the intermediate formation is the
rate limiting step.
3.5. Kinetic of the Reaction. Under the optimum conditions,
the absorbance time curves of investigated cephalosporins
with potassium permanganate reagent were constructed
(Figures 5, 6 f o rc e f o t a x i m ea sar e p r e s e n t a t i v ee x a m p l e ) .
The initial rate of the reaction was determined from the
slope of tangents of the absorption time curves. The order
of the reaction with respect to permanganate was deter-
mined by studying the reaction at diﬀerent concentrationsInternational Journal of Analytical Chemistry 5
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Table 2: Analytical parameters for the initial rate method for determination of investigated cephalosporins with alkaline potassium
permanganate.
Investigated cephalosporin
Linear range, Least square equation Correlation
M ×10
−5 log V = log K  +n log C coeﬃcient LOD μgmL −1
(μgmL −1)I n t e r c e p t ( l o g K )S l o p e ( n)( r)
Cefotaxime 1.04 to 3.14 1.918 1.007 0.9999 0.121
(5–15)
Cephapirin 1.18 to 3.54 1.866 1.010 0.9999 0.117
(5–15)
Cephradine 1.43 to 4.29 1.788 0.9942 0.9997 0.162
(5–15)
Cephalexin 1.43 to 4.31 1.856 1.001 0.9996 0.19
(5–15)
Ceftazidime 0.78 to 2.33 2.044 1.046 0.9995 0.233
(5–15)
Cefazoline 1.1 to 3.3 1.832 0.9918 0.9992 0.28
(5–15)
Ceftriaxone 0.9 to 2.7 1.884 1.009 0.9994 0.241
(5–15)
Cefuroxime 1.17 to 3.53 1.985 1.045 0.9996 0.209
(5–15)
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Figure 4: Job’s plots of continuous variation between potassium
permanganate and the studied drugs.
of permanganate with ﬁxed concentration of investigated
cephalosporins.Theplotofinitialrate(ΔA/Δt)againstinitial
absorbance was linear passing through origin indicating that
the initial order of the reaction with respect to permanganate
was 1. The order with respect to investigated cephalosporins
was evaluated by measuring the rate of the reaction at several
concentrations of cephalosporins at a ﬁxed concentration
of permanganate reagent. This was done by plotting the
logarithm of initial rate of the reaction versus logarithm
of molar concentration of investigated cephalosporins and
was found to be 1. However under the optimized exper-
imental conditions, the concentrations of cephalosporins
were determined using relative excess amount of potassium
permanganate and sodium hydroxide solutions. Therefore
pseudo-zero-order conditions were obtained with respect to
their concentrations.
3.6. Quantitation Methods
3.6.1. Initial Rate Method. The initial rate of the reaction
would follow pseudo-ﬁrst-order and were found to obey the
following equation:
ν =
ΔA
Δt
= K
 Cn,( 1 )
where ν is the reaction rate, A is the absorbance, t is the
measuring time, K  is the pseudo-ﬁrst-order rate constant,
C is the molar concentration of cephalosporins, and n is the6 International Journal of Analytical Chemistry
Table 3: Analytical parameters for ﬁxed time method of the kinetic spectrophotometric parameter for determination of investigated
cephalosporins.
Reaction
time
Linear
range
(μgmL −1)
Intercept (a)
Standard
deviation of
intercept(Sa)
Slope (b)
Standard
deviation of
slope (Sb)
Correlation
coeﬃcient (r)
LOD (μgmL −1)
Cefotaxime
35 – 2 5 0.00568 0.005827 0.02845 0.0003607 0.9993 0.6144
65 – 1 9 0.01698 0.005317 0.03472 0.0004140 0.9996 0.4590
95 – 1 7 0.02618 0.005363 0.04004 0.0004582 0.9997 0.4018
12 5–17 0.02880 0.005112 0.04516 0.0004368 0.9998 0.3395
15 5–17 0.01995 0.005112 0.05102 0.0004368 0.9998 0.3005
Cephapirin
35 – 2 5 0.00105 0.005027 0.02801 0.0003088 0.9995 0.5384
65 – 1 9 0.03286 0.004621 0.03176 0.0003598 0.9996 0.4364
95 – 1 7 0.05639 0.003562 0.03525 0.0003043 0.9998 0.30314
12 5–17 0.08327 0.003653 0.03791 0.0003121 0.9998 0.289
15 5–17 0.09054 0.003790 0.04196 0.0003238 0.9999 0.27097
Cephradine
35 – 2 5 0.01464 0.009607 0.03216 0.0005901 0.9985 0.896
65 – 1 9 0.02004 0.007665 .03856 0.0005967 0.9993 0.596
95 – 1 7 0.04891 0.005234 0.04184 0.0004471 0.9997 0.375
12 5–17 0.06645 0.004959 0.04566 0.0004237 0.9998 0.3258
15 5–17 0.07721 0.005174 0.04907 0.0004420 0.9998 0.3163
Cephalexin
35 – 2 5 0.01573 0.006484 0.03518 0.0003983 0.9994 0.5529
65 – 1 9 −0.0067 0.007189 0.04353 0.0005580 0.9995 0.495
95 – 1 7 −0.0012 0.005694 0.04841 0.0004865 0.9997 0.3528
12 5–17 −0.0040 0.005204 0.05354 0.0004446 0.9998 0.2915
15 5–17 −0.0015 0.005412 0.05821 0.0004624 0.9998 0.2789
Ceftazidime
35 – 2 5 −0.0029 0.003859 0.01905 0.0002371 0.9993 0.6077
65 – 1 9 0.03039 0.004045 0.02324 0.0003149 0.9994 0.52216
95 – 1 7 0.04486 0.003966 0.02871 0.0003388 0.9997 0.41442
12 5–17 0.06577 0.003875 0.03270 0.0003311 0.9997 0.3555
15 5–17 0.07993 0.003785 0.03636 0.0003234 0.9998 0.3128
Cefazoline
35 – 2 5 0.00027 0.006894 0.02935 0.0004235 0.9991 0.70466
65 – 1 9 0.02604 0.006741 0.03439 0.0005246 0.9993 0.588
95 – 1 7 0.03064 0.006040 0.04064 0.0005161 0.9996 0.4458
12 5–17 0.04073 0.005576 0.04566 0.0004764 0.9997 0.366
15 5–17 0.03973 0.005958 0.05038 0.0005090 0.9997 0.3547
Ceftriaxone
35 – 2 5 −0.0024 0.004203 0.02274 0.0002582 0.9994 0.55448
65 – 1 9 0.02739 0.004303 0.02770 0.0003329 0.9996 0.466
95 – 1 7 0.01350 0.004163 0.03307 0.0003557 0.9997 0.377
12 5–17 0.02534 0.004423 0.03741 0.0003779 0.9997 0.3546
15 5–17 0.03982 0.003818 0.03939 0.0003262 0.9998 0.2907International Journal of Analytical Chemistry 7
Table 3: Continued.
Reaction
time
Linear
range
(μgmL −1)
Intercept (a)
Standard
deviation of
intercept(Sa)
Slope (b)
Standard
deviation of
slope (Sb)
Correlation
coeﬃcient (r)
LOD (μgmL −1)
Cefuroxime
35 – 2 5 −0.0065 0.005980 0.02629 0.0003674 0.9991 0.68238
65 – 1 9 0.02696 0.005472 0.02994 0.00004260 0.9994 0.54829
95 – 1 7 0.04286 0.005334 0.03471 0.0004557 0.9996 0.4610
12 5–17 0.05480 0.004229 0.03845 0.0003613 0.9998 0.32996
15 5–17 0.06130 0.005614 0.04266 0.0004796 0.9997 0.2747
Table 4: Evaluation of accuracy of the analytical procedure using initial rate method.
Drug Recovery %∗
5.0μgmL −1 9.0 μgm L
−1 15.0 μgmL −1
Cefotaxime 99.8 ±1.061 100.06 ±0.7136 99.89 ±0.6435
Cephapirin 100.29 ± 1.071 99.68 ±0.7181 100.22 ±0.7661
Cephradine 100.74 ±0.8237 99.98 ±0.6211 99.87 ±0.6870
Cephalexin 99.41 ±0.7567 99.78 ±0.5612 99.73 ±0.4031
Ceftazidime 100.14 ±0.9817 100.16 ±0.8680 99.18 ±0.8714
Cefazoline 99.89 ±1.243 100.87 ±0.8745 100.4 ±0.6999
Ceftriaxone 99.31 ±1.242 99.99 ±0.9167 100.67 ±0.7308
Cefuroxime 100.21 ± 1.168 100.18 ±0.8334 100.69 ±0.9595
∗Mean of 6 replicate ± SD.
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Figure 5: Absorption versus time for the reaction between
cefotaxime (diﬀerent molar concentrations) and KMnO4 (1.8 ×
10
−3 molL
−1).
order of the reaction. The logarithmic form of the above
equation is written as follows:
Logν = log
ΔA
Δt
= log K
  +n log C. (2)
Regression analysis using the method of least square was
performed to evaluate the slopes, intercepts, and correlation
coeﬃcient.
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Figure 6: Absorption versus time for the reaction between
cefotaxime 3.14 × 10
−5 molL−1 and KMnO4 (diﬀerent molar
concentrations).
The analytical parameters and results of regression anal-
ysis are given in Table 2.Thevalueof n (≈1)in the regression
equation conﬁrmed that the reaction of cephalosporins
with the potassium permanganate was pseudo-ﬁrst-order
with respect to cephalosporins concentration. The limits
of detection (LOD) were calculated and results obtained
conﬁrmed good sensitivity of the proposed method and
consequently their capabilities to determine low amount of
cephalosporins.8 International Journal of Analytical Chemistry
3.6.2. Fixed Time Method. In this method, the absorbance
of the reaction solution containing varying amount of
cephalosporins was measured at preselected ﬁxed time.
Calibration plots of absorbance versus the concentration
of cephalosporins at ﬁxed time were established for each
investigated cephalosporins. The regression equation, corre-
lation coeﬃcients, and detection limits are given in Table 3.
The lowest detection limit was obtained at ﬁxed time of 15
minutes.Howevertheﬁxedtimeof3minutesshowedawider
concentration range for quantiﬁcation.
According to international conference of harmonization
(ICH) guideline for validation of analytical procedures
[42], the detection limit is not required to be part of
validation procedure for assay. Therefore on the basis of
wider concentration range and less time of analysis, the ﬁxed
time of 3 minutes was recommended for determination.
3.7. Validation of the Proposed Method. Concentration range
[42] is established by conﬁrming that the analytical proce-
dure provides a suitable degree of precision, accuracy, and
linearity when applied to the sample containing amount of
analyte within or at the extreme of the speciﬁed range of the
analytical procedure [43, 44]. In this work, concentrations
ranging from 7.8 × 10
−6 Mt o4 .31 × 10
−5 M were studied
for the investigated drugs in the initial rate method and
concentration ranging from 5 to 25μgmL
−1 were studied
for the investigated drugs in the ﬁxed time method (at
preselected ﬁxed time of 3 minutes). The whole set of
experiments were carried out through this range to ensure
the validation of the proposed procedure. Linear calibration
graphs were obtained for all the studied drugs by plotting the
logarithm of initial rate of the reaction versus logarithm of
molar concentration of analyte in the sample (in initial rate
method) within the speciﬁed range (Figure 7):
Logν = log
ΔA
Δt
= log K
  +n log C (where n ≈ 1) (3)
or by plotting the absorbance of the studied drugs versus
the drug concentration (in ﬁxed time method) within the
speciﬁed range (Figure 8).
Linearity was studied for both initial rate and ﬁxed time
method indicated by the values of correlation coeﬃcient (r)
and determination coeﬃcient (r2) for both method (Tables 2
and 3).
Accuracy [44] was checked at three concentration levels
within the speciﬁed range, six replicate measurements were
recorded at each concentration levels. The results were
recordedaspercentagerecovery ±standarddeviation(Tables
4 and 5).
Precision [44] was checked at three concentration levels,
eight replicate measurements were recorded at each concen-
tration level. The results are summarized in (Table 6). The
calculated relative standard deviation were all below 2.2%
indicating excellent precision of the proposed procedure at
both level of repeatability and intermediate precision.
Speciﬁcity and interference the proposed procedure was
performed in visible region away from the UV-absorption
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Figure 7: Calibration Plot of logarithm rate of the reaction
against logarithm molar concentration of cefotaxime for initial rate
method.
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Figure 8: Calibration plot of absorbance versus the concentration
of cefotaxime at preselected ﬁxed time of 3 minutes.
region of investigated drugs (228–300nm), and the interfer-
ence by reducing sugars in tablets was eliminated by extrac-
tion with methanol prior to analysis. However interference
was observed from L-arginine formulated with cephradine
in velosef vial. Therefore, the proposed procedure could not
be used for analysis of cephradine in presence of L-arginine,
except after separation by a suitable separation technique.
Limit of detection (LOD)[ 42] was calculated based on
standard deviation of response and the slope of calibration
curve [43]. The limit of detection was expressed as [44]
LOD =
3σ
S
,( 4 )
where σ is the standard deviation of intercept. S is the slope
of calibration curve.
The results were summarized in (Tables 2 and 3) indicat-
ing good sensitivity of the proposed method. According to
USP XXV validation guidelines [44], the calculatedLODval-
ues should be further validated by laboratory experiments.
In our work, good results were obtained where the calculated
drug concentration by LOD equations were actually detected
in these experiments.International Journal of Analytical Chemistry 9
Table 5: Evaluation of accuracy of the analytical procedure using ﬁxed time method.
Drug Recovery %∗
5.0μgmL −1 9.0 μgm L
−1 15.0 μgmL −1
Cefotaxime 98.75 ± 0.8183 100.98 ± 0.8118 100.75 ± 0.6424
Cephapirin 100.28 ± 1.335 99.35 ± 0.7414 100.36 ± .7051
Cephradine 100.76 ± 1.164 101.87 ± 0.9712 100.58 ± 0.8675
Cephalexin 98.59 ± 0.839 100.09 ± 0.5185 100.77 ± 0.6852
Ceftazidime 99.66 ± 1.485 100.15 ± 0.8789 99.88 ± 0.6548
Cefazoline 99.63 ± 1.262 101.42 ± 0.5617 99.44 ± 0.6155
Ceftriaxone 99.47 ± 0.9185 100.59 ± 0.9242 99.94 ± 0.5474
Cefuroxime 99.57 ± 0.9475 99.05 ± 0.9773 100.85 ± 0.7630
∗Mean of 6 replicate ± SD.
Table 6: Evaluation of precision of the initial rate and ﬁxed time methods of the proposed kinetic spectrophotometric method for
determination of investigated cephalosporins.
Drug Amount taken Recovery (% ±SD)
(μgmL −1) Initial rate method Fixed time method
Cefotaxime
5 100.1 ± 1.072 99.82 ± 0.7246
9 99.88 ± 0.6859 100.9 ± 0.7086
15 99.95 ± 0.5668 100.6 ± 0.6286
Cephapirin
5 100.16 ± 1.015 100.29 ± 1.144
9 99.68 ± 0.6840 99.2 ± 0.7160
15 100.31 ± 0.7624 100.44 ± 0.6225
Cephradine
5 100.61 ± 0.8049 100.53 ± 1.125
9 99.94 ± 0.5594 101.84 ± 0.9913
15 99.70 ± 0.6116 100.51 ± 0.9054
Cephalexin
5 99.56 ± 0.7435 98.64 ± 0.7306
9 99.78 ± 0.5811 100.04 ± 0.4796
15 99.76 ± 0.4575 100.78 ± 0.6091
Ceftazidime
5 100.2 ± 1.002 99.53 ± 1.309
9 100.19 ± 0.7958 100.6 ± 0.9820
15 99.43 ± 0.8901 99.88 ± 0.6205
Cefazoline
5 99.88 ± 1.066 99.64 ± 1.082
9 101.07 ± 0.8312 101.45 ± 0.4871
15 100.44 ± 0.7346 99.46 ± 0.5538
Ceftriaxone
5 99.28 ± 1.154 99.34 ± 0.9175
9 99.99 ± 0.8687 100.54 ± 0.8347
15 100.76 ± 0.6403 99.98 ± 0.4933
Cefuroxime
5 100.19 ± 1.19 99.52 ± 0.8834
9 100.4 ± 0.8276 99.23 ± 0.9490
15 100.39 ± 0.6692 100.94 ± 0.408
Limit of quantitation (LOQ) was calculated based on
standard deviation of intercept and slope of calibration
curve. In this method, the limit o quantitation is expressed
as [44]
LOQ =
10σ
S
. (5)
The results were summarized in (Tables 2 and 3) indicating
good sensitivity of the proposed method. According to USP
XXV validation guidelines [45], the calculated LOQ values
should be further validated by laboratory experiments. In
our work, good results were obtained where the calculated
drug concentration by LOQ equations were actually quanti-
tated in these experiments.
3.8. Application to Pharmaceutical Dosage Forms. The initial
rate and ﬁxed time methods of the proposed kinetic spec-
trophotometric method for determination of investigated
cephalosporins have been tested on commercial pharma-
ceutical dosage forms. The concentration of investigated10 International Journal of Analytical Chemistry
Table 7: Determination of studied drugs in their pharmaceutical dosage forms using initial rate and ﬁxed time methods.
Drug Pharmaceutical dosage form Proposed methods ± SD (n = 5) Reported methods ± SD
Initial rate Fixed time (n = 5)
Cefotaxime Cefotax vials
100.67 ± 0.9359 99.98 ± 1.146
100.58 ± 0.9753 t = 0.1423
∗ t = 0.8914
F = 1.086
∗ F = 1.382
Cephapirin Cefatrexyl vials
100.57 ± 0.9274 99.87 ± 1.112
100.17 ± 1.208 t = 0.5901 t = 0.4193
F = 1.698 F = 1.180
Cephradine Velosef suspension
99.85 ± 1.274 99.4 ± 1.699
99.89 ± 1.190 t = 0.1227 t = 0.5303
F = 1.346 F = 2.039
Cephradine Velosef capsuls
100.1 ± 1.071 100.56±0.6226
100.25 ± 0.7994 t = 0.2477 t = 0.6753
F = 1.793 F = 1.649
Cephalexin Ceporex vials
99.69 ± 1.0 100.43 ± 0.918
100.19 ± 0.9310 t = 0.8248 t = 0.4069
F = 1.154 F = 1.027
Cephalexin Ceporex tablets
99.93 ± 1.370 100.06 ± 1.647
99.98 ±1.112 t = 0.06844 t = 0.08551
F = 1.518 F = 2.194
Ceftazidime Fortum vials
99.2 ± 1.261 99.74 ± 1.212
99.78 ± 0.6750 t = 0.9192 t = 0.7738
F = 3.490 F = 3.222
Cefazoline Totacef vials
99.69 ± 1.586 99.35 ± 1.059
99.25 ± 1.379 t = 0.4724 t = 0.1234
F = 1.321 F = 1.695
Ceftriaxone Ceftriaxone vials
99.92 ± 1.292 99.43 ± 1.185
100.04 ±0.9742 t = 0.1658 t = 0.8951
F = 1.760 F = 1.479
Cefuroxime Zinnat vials
100.31 ± 1.091 99.82 ± 1.105
100.33 ± 0.7431 t = 0.0373 t = 0.8533
F = 2.157 F = 2.209
∗Tabulated value at 95% conﬁdence limit; t = 2.306 and F = 6.388.
cephalosporinswascomputedfromitsrespondingregression
equations. The results of proposed method (initial rate and
ﬁxedtime)werestatisticallycomparedwiththoseofreported
methods [3–5], in respect to accuracy and precision. The
obtained mean recovery values were 99.2–100.67 ± 0.6226–
1.69% (Table 7), which ensures that there is no interference
of other additives present in the studied formulations.
In the t-a n dF-tests, no signiﬁcant diﬀerences were
found between the calculated and theoretical values of both
the proposed and the reported methods at 95% conﬁdence
level. This indicates good precision and accuracy in the
analysis of investigated cephalosporins in pharmaceutical
dosage forms.
4. Conclusion
The initial rate and ﬁxed time methods can be easily applied
for determination of investigated cephalosporins in pure and
dosage forms that do not require elaborate treatment and
tedious extraction of chromophore produced. The proposed
method (initial rate or ﬁxed time) is sensitive enough
to enable determination of lower amounts of drug, theseInternational Journal of Analytical Chemistry 11
advantages encourage the application of proposed method
in routine quality control of investigated cephalosporins
in industrial laboratories. Finally our method provides
advantages of improving selectivity, avoiding interference
of colored and/or turbidity background of samples because
it measures the increase in absorbencies with time against
blank treated similarly.
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